Resolution of Cisplatin-Induced Fatigue Does Not Require Endogenous Interleukin-10 in Male MiceB

Authors

Kiersten Scott
Nabila Boukelmoune
Cullen Taniguchi
A Phillip West
Cobi J Heijnen
Robert Dantzer

Publication Date

4-27-2023

Journal

Behavioural Brain Research

Abstract

Based on previous results showing a pivotal role of endogenous interleukin-10 (IL-10) in the recovery from cisplatin-induced peripheral neuropathy, the present experiments were carried out to determine whether this cytokine plays any role in the recovery from cisplatin-induced fatigue in male mice. Fatigue was measured by decreased voluntary wheel running in mice trained to run in a wheel in response to cisplatin. Mice were treated with a monoclonal neutralizing antibody (IL-10na) administered intranasally during the recovery period to neutralize endogenous IL-10. In the first experiment, mice were treated with cisplatin (2.83 mg/kg/day) for five days and IL-10na (12 μg/day for three days) five days later. In the second experiment, they were treated with cisplatin (2.3 mg/kg/day for 5 days twice at a five-day interval) and IL10na (12 μg/day for three days) immediately after the last injection of cisplatin. In both experiments, cisplatin decreased body weight and reduced voluntary wheel running. However, IL-10na did not impair recovery from these effects. These results show that the recovery from the cisplatin-induced decrease in wheel running does not require endogenous IL-10 in contrast to the recovery from cisplatin-induced peripheral neuropathy.

Keywords

Mice, Male, Animals, Interleukin-10, Cisplatin, Motor Activity, Fatigue, Cytokines, Cisplatin, Cancer, Fatigue, Mouse, IL-10, Wheel running

Comments

PMID: 36870396